Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

YM BioSciences and Oncoscience sign licensing agreement for TheraCIM hR3

Nov. 14, 2003

Grant supports development of Resmycin

Nov. 13, 2003

Plexxikon supplies novel kinase inhibitor to Genentech

Nov. 13, 2003

Treatment under way in ML's phase II prostate cancer study

Nov. 13, 2003

Six-month Eligard product completes phase III trial

Nov. 13, 2003

Lilly scientists discover new ERbeta agonists for use in prostate cancer

Nov. 13, 2003

Phase II dose-to-rash study of Tarceva

Nov. 12, 2003

Eligard products receive Canadian approval

Nov. 12, 2003

Hybrigenics and Servier sign new drug discovery agreements

Nov. 11, 2003

New ErbB kinase inhibitors, their preparation and use revealed in AstraZeneca patent

Nov. 11, 2003

Popular Stories

Today's news in brief
BioWorld
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...